SecBot SecBot
Insider Cluster (2 insiders) ·Filed Aug 12, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago
Insider cluster: 2 insiders, $960K total
Actionable Insight • Neutral

These director sales are routine post-vesting diversification and carry no informational signal. The strong Q2 earnings beat and raised fundamentals remain the dominant narrative. Monitor for any C-suite insider activity or changes in the 10b5-1 trading plan schedule, but no action is warranted from this cluster.

DirectionNeutral
Confidencehigh
Horizonimmediate

Drugs in focus

REGN drug pipeline →

Dupixent

▲ Bullish Named in this insider cluster
Impact
Phase
Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
Time to market
Already approved and commercialized since 2017
Next catalyst
None dated

What to watchDupixent is Regeneron's most important revenue driver, generating collaboration revenue that rose 14-18% YoY in recent quarters. Investors should watch for the STYLE 1/STYLE 2 Phase 3 topline readouts for Lichen Simplex Chronicus (mid-2026) as the next label-expansion catalyst, but the main investor focus should be on Dupixent's patent cliff, earliest key patents begin expiring around 2027-2031, which will determine whether Regeneron can defend its ~$17.8B+ franchise against biosimilar entry.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$805.97
T+0 close · Aug 12, 2026 · via day close
Latest settled
+12.21%
T+60 · $904.35
Vs SPY
+17.68%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 13 $805.97entry
  2. T+1 · 3mo ago −0.31%α −0.11% · $803.48
  3. T+5 · 3mo ago +2.56%α +4.53% · $826.64
  4. T+20 · 2mo ago −3.04%α −1.29% · $781.49
  5. T+60 · 11d ago +12.21%α +17.68% · $904.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two Regeneron directors sold a combined $960K in open-market sales on August 10, 2026, following the exercise of stock options. The sales are small relative to the $82.1B market cap (0.001%) and are typical post-vesting diversification by non-executive directors. The cluster occurred 14 days after a strong Q2 earnings beat (revenue +17% YoY, EPS 40% above consensus), suggesting routine portfolio management rather than a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$960.0K
Insiders
2

Key Facts

  • Two directors sold a total of 1,200 shares for $960K on August 10, 2026
  • Sales were open-market transactions following option exercises (non-cash exercises of $0 and $287K/$301K)
  • Total sales represent ~0.001% of REGN's $82.1B market cap, well below the 0.1% materiality threshold
  • Cluster occurred 14 days after Q2 2026 earnings beat (revenue $4.29B, +17% YoY; non-GAAP EPS $14.29 vs consensus $10.20)
  • No C-suite executives participated; only two independent directors

Financial Impact

Insider sales of $960K represent 0.001% of market cap, trivial and non-material

Risk Factors

  • No material risk identified from this cluster; the trivial size and director-only composition make it non-informative

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-REGN-1786612390669

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (11h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026